Phase 3 Readout
CTTH: Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Trial on the Effic
December 30, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 30, 2026
- Company
- CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Trial on the Effic
- Indication
- Radiation-induced Lung Injury; Immune-related Pneumonia